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Smoothened inhibitors have emerged as successful treatment alternatives for Hedgehog pathway-
dependent tumors, but they are linked with the appearance of drug resistance. In this issue of Cancer Cell,
Kim and colleagues overcome such resistance by combining approved drugs itraconazole and arsenic
trioxide, thus opening a path toward new treatment options.Inappropriate reactivation of key devel-
opmental signaling pathways in cancer
is a common theme, with Hedgehog
(Hh), Wnt, and Notch pathways being
prime examples. Consequently, focused
efforts to develop inhibitors of these path-
ways are an important part of the broader
drive toward targeted therapy for cancer.
Aberrant activation of Hh signaling, most
often caused by mutational inactivation
of the Hh receptor Patched 1 (PTCH1),
is a feature of basal cell carcinoma of
the skin (BCC) and a subgroup of medul-
loblastomas (MBs). The importance of the
Hh pathway in controlling growth and
differentiation in tissue stem and progen-
itor cells is consistent with the pathway’s
role as a driver in these tumor types.
Unfortunately, as with most cancer drug
treatments, a major limitation of agents
that block Hh signaling is the presence
of preexisting or acquired drug resis-
tance, which prevent cure.
Presently, all drugs in advanced
stages of development for the treatment
of Hh pathway-dependent tumors target
Smoothened (Smo), a seven transmem-
brane G protein coupled receptor. Smo
is present at the cell membrane and is
required for ligand-dependent activationof the Hh pathway. One Smo inhibitor, vis-
modegib (GDC-0449), is FDA-approved
for the treatment of locally advanced
and metastatic BCC. Another four Smo
inhibitors have progressed into phase II
clinical trials (NVP-LDE225, IPI-926, XL-
139, and LY2940680). Two adult patients
with end-stage MB showed excellent
responses to vismodegib treatment with
tumor shrinkage lasting up to five months;
however, tumor relapse eventually
occurred in both cases (Asklund et al.,
2012; Rudin et al., 2009). More recently,
reports of vismodegib resistance in BCC
patients have also appeared (Atwood
et al., 2012). Smo inhibitor resistance
may develop by several different mecha-
nisms, including de novo mutations in
SMO, amplification of Gli2 and Ccnd1
(the cyclin D1 gene), PI3K-mTORpathway
activation, and induction of drug efflux by
P-glycoprotein (PGP) (Atwood et al.,
2012; Buonamici et al., 2010; Yauch
et al., 2009) (Figure 1). Hence, with the
anticipated increase in the clinical use of
Smo inhibitors, an increase in the preva-
lence of Smo inhibitor resistance is
expected.
In this issue of Cancer Cell, Kim et al.
(2013) present a highly relevant studyshowing that two FDA-approved drugs,
itraconazole and arsenic trioxide (ATO),
inhibit Hh pathway activation and tumor
growth associated with acquired resis-
tance to Smo antagonists. The group
had shown earlier that itraconazole, an
anti-fungal agent, inhibits Hh signaling at
the level of Smo by a mechanism different
from cyclopamine and prevents the ciliary
Smo accumulation normally resulting
from Hh activation. Functioning at a
different part of the Hh pathway, ATO
antagonizes Gli effectors downstream of
Smo by inhibiting GLI1 transcriptional
activity and blocking Hh-induced Gli2
ciliary accumulation (Beauchamp et al.,
2011; Kim et al., 2010).
Since itraconazole and ATO inhibit the
Hh pathway at distinct levels, Kim et al.
(2013) tested the two compounds alone
and in combination to assess efficacy in
tumors with acquired resistance to Smo
inhibitor. First, they showed that itracona-
zole alone blocked proliferation to similar
degrees in parental (SmoWT) and vismo-
degib-resistant (SmoD447G) MB cells
growing in spheroids derived from
Ptch+/;p53/ mice. However, a Gli-
dependent reporter-based system re-
vealed that itraconazole only partially23, January 14, 2013 ª2013 Elsevier Inc. 3
Figure 1. Itraconazole and ATO Are Effective in Treating Smo Inhibitor-Resistant Tumor
Growth by Targeting Two Different Levels of the Hh Pathway
(A) The Hedgehog signaling pathway: a simplified model. In its off state, Ptch1 inhibits Smo activity. Hh-
ligand binding to Ptch1 abrogates its inhibitory effect on Smo, allowing Smo to translocate to the primary
cilium and induce accumulation of the Gli/Sufu complex followed by nuclear translocation of Gli activators
initiating Hh-target gene transcription.
(B) Biallelic loss of PTCH1 leads to ligand-independent Smo (SmoWT) activation, promoting tumor growth.
(C) Smo inhibitors have emerged as a successful treatment alternative for Hh-pathway-dependent tumors,
with five small molecule inhibitors currently in phase II trials: vismodegib/GDC-0449, NVP-LDE225, IPI-
926, XL-139, and LY2940680.
(D) Resistance to Smo inhibitorsmay develop by several differentmechanisms, such as de novomutations
in SMO (Smomut), Gli2 and Ccnd1 (cyclin D1) amplifications, PI3K-mTOR activation, and P-glycoprotein
(PGP) induction.
(E) Kim et al. (2013) demonstrate that the combination of itraconazole and ATO significantly suppresses
Smo inhibitor-resistant tumor growth by inhibiting the Hh pathway at the level of Smo and Gli. IFT, intra-
flagellar transport; PKA, protein kinase A.
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fully inhibited. Next, the authors used
a combination of itraconazole and ATO
in an allograft model of Ptch+/;
p53/ SmoWT MB. Simultaneous treat-
ment not only inhibited tumor growth but
also reduced tumor volume by 72%. As
expected, Hh pathway activity was most
efficiently inhibited after treatment with
both itraconazole and ATO. The authors
then confirmed the beneficial combi-
natorial effect using a second Hh
pathway-dependent tumor model based
on allografted BCC cells derived from
Ptch+/;K14-CreER/+;p53fl/fl mice.4 Cancer Cell 23, January 14, 2013 ª2013 ElTo answer the key question if combined
itraconazole and ATO treatment is able
to block growth of tumors with acquired
Smo inhibitor resistance, the authors
treated mice bearing allografts of Ptch+/;
p53/ SmoD447G MB. Unlike the result
with vismodegib, itraconazole and ATO
treatment substantially reduced tumor
growth, causing a 48% reduction in the
original tumor size and a 66% reduction
in Hh pathway activity.
Since medulloblastoma is an intracra-
nial malignancy, which is potentially not
well represented by subcutaneous allo-
grafts, Kim et al. (2013) also tested treat-sevier Inc.ment efficacy in an orthotopic SmoD447G
MB model. They observed that mice
receiving single agent treatment with itra-
conazole or ATO had significantly
improved survival over control mice (22
and 18 days versus 14 days). Importantly,
the combination of the drugs further
improved the median survival to 29 days
before death due to an excessive tumor
burden. Of note, no indications of activa-
tion of previously described resistance
mechanisms, specifically PI3K-mTOR
activity or increased Gli2 mRNA expres-
sion, was observed, and drug efflux via
PGP is unlikely since itraconazole is
a potent inhibitor of PGP. This leaves
incomplete pathway inhibition as a likely
reason underlying continued tumor
growth.
In sum, the combination of itraconazole
and ATO showed a significant suppres-
sive effect on tumor growth in preclinical
models and, very encouragingly, the
suppressive effect overcomes all known
drug-resistant Smo mutations and is
sustained in the context of Gli2
overexpression.
Both itraconazole and ATO have
several additional cellular targets that
may play a role in the inhibition of tumor
growth. In the case of itraconazole, this
includes VEGFR2 and cytochrome P450
retinoic acid metabolizing enzymes, and
PML, NF-kB, and microtubules in the
case of ATO. Future studies utilizing
more selective means to target the down-
stream components of the Hh pathway,
such as RNAi or small molecules, should
be informative. A key question in this
context is the extent to which resistant
tumors will remain dependent on high
levels of canonical Hh-signaling. Given
the now well-established heterogeneity
and plasticity of tumor cells, mechanisms
to evade exclusive dependence on
a single signaling pathway are likely to
evolve. This possibility is supported by
response rates in the range of 30%–40%
and a limited duration of response in clin-
ical trials treating BCCwith Smo inhibitors
(Atwood et al., 2012).
The best option to combat Hh-depen-
dent tumors may therefore be to inhibit
the Hh pathway very effectively from the
start, hoping to prevent development of
resistance. In this scenario, the combina-
torial use of inhibitors targeting different
steps in the signaling pathway, as in the
study by Kim et al. (2013), is attractive.
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PreviewsGiven the existence of multiple Smo-inde-
pendent mechanisms of Hh pathway acti-
vation, such as gene amplification or
increased activity of the Gli transcription
factors as well as inactivation of the
intracellular repressor Sufu, inhibition
of Gli transcriptional effectors appears
appealing. Of relevance, activation of the
S6K1 kinase in the PI3K/mTOR pathway
has recently been shown to increase
active GLI1 levels (Wang et al., 2012),
which may contribute to the observed
Smo inhibitor resistance caused by
increased PI3K/mTOR signaling.
A concern with regard to the clinical use
of Smo inhibitors is side-effects such as
weight loss and muscle cramping that
have no known connection to canonical
Hh-signaling. Smo-dependent activation
of AMPK and Ca2+ influx in brown fat
and muscle cells elicited by several Smo
inhibitors is now proposed as an under-
lying mechanism (Teperino et al., 2012).Investigation of the presence or absence
of such activity induced by itraconazole
is therefore warranted.
The findings by Kim et al. (2013) are,
despite unanswered questions, very en-
couraging in that they suggest immedi-
ately available second-line treatment
options for Smo inhibitor-resistant tumors
to be evaluated in the clinical setting.
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In this issue of Cancer Cell, Liang and colleagues demonstrated that sphingosine kinase 1, the enzyme that
catalyzes formation of the biologically active lipid sphingosine 1-phosphate, drives a malicious amplification
loop involving sphingosine 1-phosphate receptor 1 and the NF-kB/IL-6/STAT3 pathway. This appears critical
for progression from chronic inflammation to colon cancer.There is substantial evidence linking
inflammatory bowel disease, particularly
ulcerative colitis (UC), with colon cancer,
termed colitis-associated cancer (CAC).
In this regard, mucosal inflammatory cell
types can promote (regulatory T cells
[Tregs], type 2 macrophages, CD4+ T
helper [Th-17 cells]) or inhibit (CD8+
T cells, natural killer cells) CAC (Monte-
leone et al., 2012). The regulatory effects
of inflammatory cells on the growth and
survival of cancer cells is dependent on
cytokines that can act directly or indi-rectly on these cells. For instance, cyto-
kines such as interleukin-6 (IL-6) and
tumor necrosis factor-alpha (TNF-a)
provide a supportive tumor microenviron-
ment by activating the transcription
factors NF-kB and STAT3, and these are
involved in the development of CAC. Acti-
vation of NF-kB in a tumor microenviron-
ment is associated with enhanced inflam-
mation and release of IL-6, which
promotes CAC (Monteleone et al., 2012).
In this issue of Cancer Cell, Liang
et al. (2013) elegantly demonstrate thatthe sphingosine 1-phosphate receptor 1
(S1PR1) and sphingosine kinase 1
(SphK1), the enzyme that catalyzes the
formation of sphingosine 1-phosphate
(S1P, the natural ligand of S1PR1), are
a missing link between chronic inflamma-
tion and CAC. Indeed, there is sub-
stantial evidence for a role of SphK1 and
S1P in cancer (Pyne and Pyne, 2010).
There were two important findings that
preceded the current study. First, Kawa-
mori et al. (2009) demonstrated that
Sphk1 knockout mice exhibit reduced23, January 14, 2013 ª2013 Elsevier Inc. 5
